메뉴 건너뛰기




Volumn 71, Issue 5, 2013, Pages 1357-1368

The interaction of bortezomib with multidrug transporters: Implications for therapeutic applications in advanced multiple myeloma and other neoplasias

Author keywords

Bortezomib; Co culture; Elacridar; MDR protein; P glycoprotein

Indexed keywords

BORTEZOMIB; BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123;

EID: 84877927768     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2136-7     Document Type: Article
Times cited : (57)

References (51)
  • 2
    • 34249324102 scopus 로고    scopus 로고
    • The pharmacology of cancer resistance
    • 17593618
    • O'Connor R (2007) The pharmacology of cancer resistance. Anticancer Res 27:1267-1272
    • (2007) Anticancer Res , vol.27 , pp. 1267-1272
    • O'Connor, R.1
  • 3
    • 0642378063 scopus 로고    scopus 로고
    • Overcoming drug resistance in multiple myeloma: The emergence of therapeutic approaches to induce apoptosis
    • 14615454 10.1200/JCO.2003.06.001 1:CAS:528:DC%2BD2cXpsVajt74%3D
    • Yang HH, Ma MH, Vescio RA, Berenson JR (2003) Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol 21:4239-4247
    • (2003) J Clin Oncol , vol.21 , pp. 4239-4247
    • Yang, H.H.1    Ma, M.H.2    Vescio, R.A.3    Berenson, J.R.4
  • 4
    • 0027507266 scopus 로고
    • P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy
    • 8093668 1:STN:280:DyaK3s7js1Cguw%3D%3D
    • Grogan TM, Spier CM, Salmon SE et al (1993) P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 81:490-495
    • (1993) Blood , vol.81 , pp. 490-495
    • Grogan, T.M.1    Spier, C.M.2    Salmon, S.E.3
  • 5
    • 0035673972 scopus 로고    scopus 로고
    • Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: An EORTC-HOVON randomized phase III study (06914)
    • 11843823 10.1046/j.1365-2141.2001.03171.x 1:CAS:528: DC%2BD38XltlCktg%3D%3D
    • Sonneveld P, Suciu S, Weijermans P et al (2001) Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol 115:895-902
    • (2001) Br J Haematol , vol.115 , pp. 895-902
    • Sonneveld, P.1    Suciu, S.2    Weijermans, P.3
  • 6
    • 0028816350 scopus 로고
    • A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study
    • 7828131 10.1002/1097-0142(19950201)75:3<815: AID-CNCR2820750311>3. 0.CO;2-R 1:STN:280:DyaK2M7ivFSgug%3D%3D
    • Dalton WS, Crowley JJ, Salmon SS et al (1995) A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 75:815-820
    • (1995) Cancer , vol.75 , pp. 815-820
    • Dalton, W.S.1    Crowley, J.J.2    Salmon, S.S.3
  • 7
    • 32544437036 scopus 로고    scopus 로고
    • Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): A trial of the Eastern Cooperative Oncology Group
    • 16419071 10.1002/cncr.21666
    • Friedenberg WR, Rue M, Blood EA et al (2006) Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 106:830-838
    • (2006) Cancer , vol.106 , pp. 830-838
    • Friedenberg, W.R.1    Rue, M.2    Blood, E.A.3
  • 8
    • 10344248680 scopus 로고    scopus 로고
    • Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase i study
    • 8892677 1:STN:280:DyaK2s%2FkslygtA%3D%3D
    • Sonneveld P, Marie JP, Huisman C et al (1996) Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 10:1741-1750
    • (1996) Leukemia , vol.10 , pp. 1741-1750
    • Sonneveld, P.1    Marie, J.P.2    Huisman, C.3
  • 9
    • 34547505458 scopus 로고    scopus 로고
    • Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors
    • 17662692 10.1016/j.bbrc.2007.07.049 1:CAS:528:DC%2BD2sXosF2jtLs%3D
    • Rumpold H, Salvador C, Wolf AM, Tilg H, Gastl G, Wolf D (2007) Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun 361:549-554
    • (2007) Biochem Biophys Res Commun , vol.361 , pp. 549-554
    • Rumpold, H.1    Salvador, C.2    Wolf, A.M.3    Tilg, H.4    Gastl, G.5    Wolf, D.6
  • 10
    • 0032862993 scopus 로고    scopus 로고
    • The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: Potential for a role in cancer chemotherapy
    • 10506575 1:CAS:528:DyaK1MXms1Ohsr8%3D
    • Loo TW, Clarke DM (1999) The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. FASEB J 13:1724-1732
    • (1999) FASEB J , vol.13 , pp. 1724-1732
    • Loo, T.W.1    Clarke, D.M.2
  • 11
    • 0032127153 scopus 로고    scopus 로고
    • Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs)
    • 9849488 10.1016/S0959-8049(98)00045-8 1:CAS:528:DyaK1cXltlCgsro%3D
    • Duffy CP, Elliott CJ, O'Connor RA et al (1998) Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 34:1250-1259
    • (1998) Eur J Cancer , vol.34 , pp. 1250-1259
    • Duffy, C.P.1    Elliott, C.J.2    O'Connor, R.A.3
  • 12
    • 0027027092 scopus 로고
    • Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A
    • 1369413 10.1007/BF00376102 1:STN:280:DyaK3s7jsF2qsg%3D%3D
    • Clynes M, Redmond A, Moran E, Gilvarry U (1992) Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A. Cytotechnology 10:75-89
    • (1992) Cytotechnology , vol.10 , pp. 75-89
    • Clynes, M.1    Redmond, A.2    Moran, E.3    Gilvarry, U.4
  • 13
    • 34249320200 scopus 로고    scopus 로고
    • Proteomic analysis to dissect mitoxantrone resistance-associated proteins in a squamous lung carcinoma
    • 17593620 1:CAS:528:DC%2BD2sXmslKju7c%3D
    • Murphy L, Clynes M, Keenan J (2007) Proteomic analysis to dissect mitoxantrone resistance-associated proteins in a squamous lung carcinoma. Anticancer Res 27:1277-1284
    • (2007) Anticancer Res , vol.27 , pp. 1277-1284
    • Murphy, L.1    Clynes, M.2    Keenan, J.3
  • 14
    • 77956627713 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines
    • Collins DM, Crown J, O'Donovan N et al (2010) Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines. Invest New Drugs 28(4):433-444
    • (2010) Invest New Drugs , vol.28 , Issue.4 , pp. 433-444
    • Collins, D.M.1    Crown, J.2    O'Donovan, N.3
  • 15
    • 0033000043 scopus 로고    scopus 로고
    • Idarubicin overcomes P-glycoprotein-related multidrug resistance: Comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines
    • 10374847 10.1016/S0145-2126(99)00041-7 1:CAS:528:DyaK1MXktVSkur4%3D
    • Roovers DJ, van Vliet M, Bloem AC, Lokhorst HM (1999) Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. Leuk Res 23:539-548
    • (1999) Leuk Res , vol.23 , pp. 539-548
    • Roovers, D.J.1    Van Vliet, M.2    Bloem, A.C.3    Lokhorst, H.M.4
  • 16
    • 0036195976 scopus 로고    scopus 로고
    • Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6G accumulation in breast cancer cells that overexpress P-glycoprotein
    • 11897053 1:CAS:528:DC%2BD38XislSnu7w%3D
    • Sarver JG, Klis WA, Byers JP, Erhardt PW (2002) Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6G accumulation in breast cancer cells that overexpress P-glycoprotein. J Biomol Screen 7:29-34
    • (2002) J Biomol Screen , vol.7 , pp. 29-34
    • Sarver, J.G.1    Klis, W.A.2    Byers, J.P.3    Erhardt, P.W.4
  • 17
    • 0025774712 scopus 로고
    • Acid phosphatase: Endpoint for in vitro toxicity tests
    • 2033016 10.1007/BF02630912 1:STN:280:DyaK3M3js1KgtQ%3D%3D
    • Martin A, Clynes M (1991) Acid phosphatase: endpoint for in vitro toxicity tests. In Vitro Cell Dev Biol 27A:183-184
    • (1991) Vitro Cell Dev Biol , vol.27 , pp. 183-184
    • Martin, A.1    Clynes, M.2
  • 18
    • 77950542260 scopus 로고    scopus 로고
    • Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
    • McMillin DW, Delmore J, Weisberg E et al (2010) Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 16:483-489
    • (2010) Nat Med , vol.16 , pp. 483-489
    • McMillin, D.W.1    Delmore, J.2    Weisberg, E.3
  • 19
    • 67650995912 scopus 로고    scopus 로고
    • Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
    • 19584292 10.1158/0008-5472.CAN-08-4285 1:CAS:528:DC%2BD1MXosV2msbw%3D
    • McMillin DW, Ooi M, Delmore J et al (2009) Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 69:5835-5842
    • (2009) Cancer Res , vol.69 , pp. 5835-5842
    • McMillin, D.W.1    Ooi, M.2    Delmore, J.3
  • 20
    • 73149116617 scopus 로고    scopus 로고
    • Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib
    • Ooi MG, Hayden PJ, Kotoula V et al (2009) Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res 15(23):7153-7160
    • (2009) Clin Cancer Res , vol.15 , Issue.23 , pp. 7153-7160
    • Ooi, M.G.1    Hayden, P.J.2    Kotoula, V.3
  • 21
    • 33646055171 scopus 로고    scopus 로고
    • Cell-cell contact mediated signalling - No fear of contact
    • 16614701 1:CAS:528:DC%2BD28Xltlaktrc%3D
    • Schmidmaier R, Baumann P, Meinhardt G (2006) Cell-cell contact mediated signalling - no fear of contact. Exp Oncol 28:12-15
    • (2006) Exp Oncol , vol.28 , pp. 12-15
    • Schmidmaier, R.1    Baumann, P.2    Meinhardt, G.3
  • 22
    • 0000994406 scopus 로고
    • Analysis of combined drug effects: A new look at a very old problem
    • 10.1016/0165-6147(83)90490-X 1:CAS:528:DyaL2cXhslWhsA%3D%3D
    • Chou TC, Talalay P (1983) Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4:450-454
    • (1983) Trends Pharmacol Sci , vol.4 , pp. 450-454
    • Chou, T.C.1    Talalay, P.2
  • 23
    • 0021118703 scopus 로고
    • Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
    • 10.1016/0065-2571(84)90007-4 1:CAS:528:DyaL2cXktlaksLk%3D
    • Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 22:27-55
    • (1984) Adv Enzym Regul , vol.22 , pp. 27-55
    • Chou, T.C.1    Talalay, P.2
  • 24
    • 34547106018 scopus 로고    scopus 로고
    • Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
    • 17646864 10.1038/nrc2189 1:CAS:528:DC%2BD2sXotVKqsrw%3D
    • Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7:585-598
    • (2007) Nat Rev Cancer , vol.7 , pp. 585-598
    • Hideshima, T.1    Mitsiades, C.2    Tonon, G.3    Richardson, P.G.4    Anderson, K.C.5
  • 25
    • 35848931009 scopus 로고    scopus 로고
    • The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells
    • 17786311 1:CAS:528:DC%2BD2sXht1SjurbN
    • Nakamura T, Tanaka K, Matsunobu T et al (2007) The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. Int J Oncol 31:803-811
    • (2007) Int J Oncol , vol.31 , pp. 803-811
    • Nakamura, T.1    Tanaka, K.2    Matsunobu, T.3
  • 26
    • 77957362892 scopus 로고    scopus 로고
    • Increased ABCB1 expression in TP-110-resistant RPMI-8226 cells
    • 20834157 10.1271/bbb.100325 1:CAS:528:DC%2BC3cXht12qs7%2FF
    • Iijima M, Momose I, Ikeda D (2010) Increased ABCB1 expression in TP-110-resistant RPMI-8226 cells. Biosci Biotechnol Biochem 74:1913-1919
    • (2010) Biosci Biotechnol Biochem , vol.74 , pp. 1913-1919
    • Iijima, M.1    Momose, I.2    Ikeda, D.3
  • 28
    • 67651009562 scopus 로고    scopus 로고
    • In vitro activity of bortezomib in cultures of patient tumour cells - Potential utility in haematological malignancies
    • 19016012 10.1007/s12032-008-9107-6 1:CAS:528:DC%2BD1MXmtVKitrg%3D
    • Wiberg K, Carlson K, Aleskog A, Larsson R, Nygren P, Lindhagen E (2009) In vitro activity of bortezomib in cultures of patient tumour cells - potential utility in haematological malignancies. Med Oncol 26:193-201
    • (2009) Med Oncol , vol.26 , pp. 193-201
    • Wiberg, K.1    Carlson, K.2    Aleskog, A.3    Larsson, R.4    Nygren, P.5    Lindhagen, E.6
  • 29
    • 27144531388 scopus 로고    scopus 로고
    • Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance
    • 15945097 10.1002/ijc.21063 1:CAS:528:DC%2BD2MXhtFKjs7jN
    • Fujita T, Washio K, Takabatake D et al (2005) Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. Int J Cancer 117:670-682
    • (2005) Int J Cancer , vol.117 , pp. 670-682
    • Fujita, T.1    Washio, K.2    Takabatake, D.3
  • 30
    • 77249141699 scopus 로고    scopus 로고
    • The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02
    • Lu S, Chen Z, Yang J et al (2010) The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02. Int J Lab Hematol 32(1 pt 1):e123-131
    • (2010) Int J Lab Hematol , vol.32 , Issue.1 PART 1
    • Lu, S.1    Chen, Z.2    Yang, J.3
  • 31
    • 34248377893 scopus 로고    scopus 로고
    • Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status
    • 17096161 10.1007/s00280-006-0367-6 1:CAS:528:DC%2BD2sXltFSkt7w%3D
    • Minderman H, Zhou Y, O'Loughlin KL, Baer MR (2007) Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother Pharmacol 60:245-255
    • (2007) Cancer Chemother Pharmacol , vol.60 , pp. 245-255
    • Minderman, H.1    Zhou, Y.2    O'Loughlin, K.L.3    Baer, M.R.4
  • 32
    • 0037443551 scopus 로고    scopus 로고
    • The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications
    • 12424198 10.1182/blood-2002-06-1768 1:CAS:528:DC%2BD3sXit1egt70%3D
    • Mitsiades N, Mitsiades CS, Richardson PG et al (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377-2380
    • (2003) Blood , vol.101 , pp. 2377-2380
    • Mitsiades, N.1    Mitsiades, C.S.2    Richardson, P.G.3
  • 33
    • 0036017506 scopus 로고    scopus 로고
    • Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma
    • 12180485 10.1385/MO:19:2:87 1:CAS:528:DC%2BD38XmtF2iu7Y%3D
    • Schwarzenbach H (2002) Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol 19:87-104
    • (2002) Med Oncol , vol.19 , pp. 87-104
    • Schwarzenbach, H.1
  • 34
    • 0037150228 scopus 로고    scopus 로고
    • Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling
    • 11960367 10.1038/sj.onc.1205117 1:CAS:528:DC%2BD38XivVeltbs%3D
    • Kuo MT, Liu Z, Wei Y et al (2002) Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene 21:1945-1954
    • (2002) Oncogene , vol.21 , pp. 1945-1954
    • Kuo, M.T.1    Liu, Z.2    Wei, Y.3
  • 35
    • 0034695660 scopus 로고    scopus 로고
    • Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis
    • 10636889 10.1074/jbc.275.3.1887 1:CAS:528:DC%2BD3cXotFWqtA%3D%3D
    • Thevenod F, Friedmann JM, Katsen AD, Hauser IA (2000) Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. J Biol Chem 275:1887-1896
    • (2000) J Biol Chem , vol.275 , pp. 1887-1896
    • Thevenod, F.1    Friedmann, J.M.2    Katsen, A.D.3    Hauser, I.A.4
  • 36
    • 0034994147 scopus 로고    scopus 로고
    • Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling
    • 11391531 10.1053/jhep.2001.24667 1:CAS:528:DC%2BD3MXktlygt7Y%3D
    • Ros JE, Schuetz JD, Geuken M et al (2001) Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling. Hepatology 33:1425-1431
    • (2001) Hepatology , vol.33 , pp. 1425-1431
    • Ros, J.E.1    Schuetz, J.D.2    Geuken, M.3
  • 37
    • 45349092338 scopus 로고    scopus 로고
    • Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp
    • 18296917 10.4161/cbt.7.4.5483 1:CAS:528:DC%2BD1cXhtVSktL3I
    • Zhang Y, Shi Y, Li X et al (2008) Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp. Cancer Biol Ther 7:540-546
    • (2008) Cancer Biol Ther , vol.7 , pp. 540-546
    • Zhang, Y.1    Shi, Y.2    Li, X.3
  • 38
    • 0037427122 scopus 로고    scopus 로고
    • NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells
    • 12527911 10.1038/sj.onc.1206056 1:CAS:528:DC%2BD3sXjtlCrtQ%3D%3D
    • Bentires-Alj M, Barbu V, Fillet M et al (2003) NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22:90-97
    • (2003) Oncogene , vol.22 , pp. 90-97
    • Bentires-Alj, M.1    Barbu, V.2    Fillet, M.3
  • 39
    • 0018840710 scopus 로고
    • Characterization of marrow stromal (fibroblastoid) cells and their association with erythropoiesis
    • 7461050 1:STN:280:DyaL3M7hsVClsg%3D%3D
    • Werts ED, DeGowin RL, Knapp SK, Gibson DP (1980) Characterization of marrow stromal (fibroblastoid) cells and their association with erythropoiesis. Exp Hematol 8:423-433
    • (1980) Exp Hematol , vol.8 , pp. 423-433
    • Werts, E.D.1    Degowin, R.L.2    Knapp, S.K.3    Gibson, D.P.4
  • 40
    • 0030041147 scopus 로고    scopus 로고
    • Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B
    • 8562936 1:CAS:528:DyaK28XnsFGmsQ%3D%3D
    • Chauhan D, Uchiyama H, Akbarali Y et al (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87:1104-1112
    • (1996) Blood , vol.87 , pp. 1104-1112
    • Chauhan, D.1    Uchiyama, H.2    Akbarali, Y.3
  • 41
    • 0035958517 scopus 로고    scopus 로고
    • The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications
    • 11494147 10.1038/sj.onc.1204623 1:CAS:528:DC%2BD3MXlvVGktr4%3D
    • Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC (2001) The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20:4519-4527
    • (2001) Oncogene , vol.20 , pp. 4519-4527
    • Hideshima, T.1    Chauhan, D.2    Schlossman, R.3    Richardson, P.4    Anderson, K.C.5
  • 42
    • 0030026437 scopus 로고    scopus 로고
    • Transforming growth factor-beta1: Differential effects on multiple myeloma versus normal B cells
    • 8634441 1:CAS:528:DyaK28XhtlGgsb8%3D
    • Urashima M, Ogata A, Chauhan D et al (1996) Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood 87:1928-1938
    • (1996) Blood , vol.87 , pp. 1928-1938
    • Urashima, M.1    Ogata, A.2    Chauhan, D.3
  • 43
    • 13544255403 scopus 로고    scopus 로고
    • The pathophysiologic role of VEGF in hematologic malignancies: Therapeutic implications
    • 15471951 10.1182/blood-2004-07-2909 1:CAS:528:DC%2BD2MXhsVChtrc%3D
    • Podar K, Anderson KC (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105:1383-1395
    • (2005) Blood , vol.105 , pp. 1383-1395
    • Podar, K.1    Anderson, K.C.2
  • 44
    • 79955974540 scopus 로고    scopus 로고
    • Lenalidomide targets clonogenic side population in multiple myeloma: Pathophysiologic and clinical implications
    • 21321360 10.1182/blood-2010-02-267344 1:CAS:528:DC%2BC3MXlvFKmu7o%3D
    • Jakubikova J, Adamia S, Kost-Alimova M et al (2011) Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 117:4409-4419
    • (2011) Blood , vol.117 , pp. 4409-4419
    • Jakubikova, J.1    Adamia, S.2    Kost-Alimova, M.3
  • 45
    • 84875174768 scopus 로고    scopus 로고
    • The role of tumour-stromal interactions in modifying drug response: Challenges and oppurtunities
    • McMillin DW, Negri JM, Mitsiades CS (2013) The role of tumour-stromal interactions in modifying drug response: challenges and oppurtunities. Nat Rev Drug Discov 12(3):217-228
    • (2013) Nat Rev Drug Discov , vol.12 , Issue.3 , pp. 217-228
    • McMillin, D.W.1    Negri, J.M.2    Mitsiades, C.S.3
  • 47
    • 0033603195 scopus 로고    scopus 로고
    • Role of SR-4987 stromal cells in the modulation of doxorubicin toxicity to in vitro granulocyte-macrophage progenitors (CFU-GM)
    • 10462078 10.1016/S0024-3205(99)00272-6 1:CAS:528:DyaK1MXksVemsrs%3D
    • Pessina A, Piccirillo M, Mineo E et al (1999) Role of SR-4987 stromal cells in the modulation of doxorubicin toxicity to in vitro granulocyte- macrophage progenitors (CFU-GM). Life Sci 65:513-523
    • (1999) Life Sci , vol.65 , pp. 513-523
    • Pessina, A.1    Piccirillo, M.2    Mineo, E.3
  • 48
    • 76249085456 scopus 로고    scopus 로고
    • Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma
    • Perez LE, Parquet N, Meads M, Anasetti C, Dalton W (2010) Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. Eur J Haematol 84(3):212-222
    • (2010) Eur J Haematol , vol.84 , Issue.3 , pp. 212-222
    • Perez, L.E.1    Parquet, N.2    Meads, M.3    Anasetti, C.4    Dalton, W.5
  • 49
    • 56949101068 scopus 로고    scopus 로고
    • PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines
    • 18640717 10.1016/j.leukres.2008.06.010 1:CAS:528:DC%2BD1cXhsVChtrvF
    • Garcia MG, Alaniz LD, Cordo Russo RI, Alvarez E, Hajos SE (2009) PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines. Leuk Res 33:288-296
    • (2009) Leuk Res , vol.33 , pp. 288-296
    • Garcia, M.G.1    Alaniz, L.D.2    Cordo Russo, R.I.3    Alvarez, E.4    Hajos, S.E.5
  • 50
    • 0028061548 scopus 로고
    • P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder
    • 7848886 1:STN:280:DyaK2M7ltFKjsA%3D%3D
    • Petrylak DP, Scher HI, Reuter V, O'Brien JP, Cordon-Cardo C (1994) P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann Oncol 5:835-840
    • (1994) Ann Oncol , vol.5 , pp. 835-840
    • Petrylak, D.P.1    Scher, H.I.2    Reuter, V.3    O'Brien, J.P.4    Cordon-Cardo, C.5
  • 51
    • 79955822004 scopus 로고    scopus 로고
    • Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma
    • 21482978 10.1200/JCO.2010.34.0760
    • Mitsiades CS, Davies FE, Laubach JP et al (2011) Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 29:1916-1923
    • (2011) J Clin Oncol , vol.29 , pp. 1916-1923
    • Mitsiades, C.S.1    Davies, F.E.2    Laubach, J.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.